NASDAQ:ASBP 11 November 2025 - 15 December 2025

Aspire Biopharma shares fell about 8% to $0.095 on December 15, 2025, as the company’s stock transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market. Aspire faces Nasdaq deadlines to regain compliance with minimum bid price and equity rules by early 2026. The company is also advancing an FDA regulatory milestone for its sublingual aspirin program.

Aspire Biopharma Holdings (NASDAQ: ASBP) surged over 30% in pre-market trading Friday after announcing a new $100 million equity line of credit with Arena Business Solutions and releasing its Q3 2025 10-Q. Shares traded around $0.14, up from Thursday’s $0.11 close, with market cap near $5.3 million. The new deal replaces a prior ELOC signed in February.

ASBP shares dropped roughly 20–25% mid-session Nov. 11, trading on heavy volume and swinging between $0.1189 and $0.2471. No new company news was released; the last updates were last week’s CPHI Frankfurt partnering recap and special meeting results. Nasdaq delisting risk remains after Aspire requested a hearing to contest compliance failures.